Pr. Emilio Perucca, MD, PhD is Adjunct Professor in the Department of Neuroscience, Monash University, Melbourne, Australia, and an external advisor to the European Medicines Agency (EMA). He is a Past-President of the International League against Epilepsy (ILAE) and a member of the ILAE Finance Committee and of the ILAE Advocacy Council. Pr. Perucca is Associate Editor of Epileptic Disorder and a member of the Editorial Board of several other journals, including Lancet Neurology, CNS Drugs, Seizure and Epilepsy Research. He is also a member of the Board of Directors of the ROW Foundation (Chicago). Between 2000 and 2008 he served two terms as member of the Executive Council of the Clinical Pharmacology Section of the International Union of Pharmacology Societies (IUPHAR). He received the Ambassador for Epilepsy Award from ILAE and from the International Epilepsy Bureau in 1997, the ILAE European Epileptology Award in 2018, and the Lifetime Accelerator Award from the Epilepsy Foundation (U.S.A.) in 2021. He co-edited or contributed to several international textbooks and authored or co-authored over 500 Pubmed-listed publications in the field of clinical pharmacology and epilepsy therapy, with an H-Index of 82 and a Citation Index over 28,000. Pr. Perucca’s research activities have focused on the clinical pharmacology of antiepileptic drugs, the drug treatment of seizure disorders, clinical trial methodology and assessment of outcome in people with epilepsy.
Pr. Sylvain Rheims, MD, PhD, is head of the Functional Neurology and Epilepsy Department in Lyon, one of the most active epilepsy surgery center in Europe, and co-chair of an INSERM/CNRS laboratory specialized in translational research in epilepsy (TIGER, CRNL, INSERM U1025, CNRS 5292). He coordinates in Lyon the French National Reference Center for Rare Epilepsies and is deeply involved in the European Reference Network for rare and complex epilepsies (EPICARE), especially in the field of epilepsy surgery and clinical trials. Pr. Rheims has published 96 Pubmed referenced papers, including 49 as first or last authors. His clinical research skills cover both the fields of clinical epilepsy, including SUDEP, epilepsy surgery and clinical trials, but also biostatistics (including meta-analysis), and experimental epilepsy. His main research topics are evaluation of efficacy and safety of new antiepileptic treatments and development of innovative therapeutic strategies for epilepsy comorbidities, especially in the field of SUDEP. He received in 2018 the ILAE-CEA European Young Investigator Award.
Dr. Yusuf Hannun, MD, is an internationally-known researcher in the area of lipids, protein kinases and signal transduction. His current research, supported by five National Institutes of Health grants totaling $1.7 million, focuses on lipid signaling mechanisms and networks, to potentially create highly targeted therapies for cancer, neurological disorders, inflammation and metabolic disorders. His novel contributions to science in the field of lipid biology have opened up a new field of investigation centered on the study of sphingolipids and their roles in cancer biology, inflammation, and cancer therapeutics. Prior to joining Stony Brook University, Dr. Hannun served as Senior Associate Dean for Research at the Medical University of South Carolina where he also served as the Ralph F. Hirschmann Chair and Distinguished University Professor of Biomedical Research and the chairman of the Department of Biochemistry and Molecular Biology for 14 years. Dr. Hannun has published more than 550 scientific manuscripts, edited 7 books and authored 7 patents. Dr. Hannun also received numerous scientific and professional honors.